Literature DB >> 31189043

Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.

Joe-Elie Salem1, Yves Allenbach1, Aurore Vozy1, Nicolas Brechot2, Douglas B Johnson3, Javid J Moslehi3, Mathieu Kerneis2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31189043     DOI： 10.1056/NEJMc1901677

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  95 in total

Review 1.  [Novel cancer treatment and the cardiovascular risk : What should cardiologists know?]

Authors:  Matthias Totzeck; Tienush Rassaf
Journal:  Herz       Date:  2020-04       Impact factor: 1.443

Review 2.  [Mechanisms of cardiotoxicity of oncological therapies].

Authors:  L H Lehmann; S Fröhling
Journal:  Internist (Berl)       Date:  2020-11       Impact factor: 0.743

3.  Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.

Authors:  Amy Cunningham-Bussel; Jiaqi Wang; Lauren C Prisco; Lily W Martin; Kathleen M M Vanni; Alessandra Zaccardelli; Mazen Nasrallah; Lydia Gedmintas; Lindsey A MacFarlane; Nancy A Shadick; Mark M Awad; Osama Rahma; Nicole R LeBoeuf; Ellen M Gravallese; Jeffrey A Sparks
Journal:  Arthritis Rheumatol       Date:  2022-01-25       Impact factor: 10.995

4.  Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.

Authors:  Ranjan Pathak; Anjan Katel; Erminia Massarelli; Victoria M Villaflor; Virginia Sun; Ravi Salgia
Journal:  Oncologist       Date:  2021-08-25

Review 5.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

Review 6.  The cancer patient and cardiology.

Authors:  José Luis Zamorano; Christer Gottfridsson; Riccardo Asteggiano; Dan Atar; Lina Badimon; Jeroen J Bax; Daniela Cardinale; Antonella Cardone; Elizabeth A M Feijen; Péter Ferdinandy; Teresa López-Fernández; Chris P Gale; John H Maduro; Javid Moslehi; Torbjørn Omland; Juan Carlos Plana Gomez; Jessica Scott; Thomas M Suter; Giorgio Minotti
Journal:  Eur J Heart Fail       Date:  2020-10-02       Impact factor: 15.534

Review 7.  Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature.

Authors:  Karmela Kim Chan; Cynthia Magro; Alexander Shoushtari; Charles Rudin; Veronica Rotemberg; Anthony Rossi; Cecilia Lezcano; John Carrino; David Fernandez; Michael A Postow; Arlyn Apollo; Mario E Lacouture; Anne R Bass
Journal:  Oncologist       Date:  2019-10-15

Review 8.  Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.

Authors:  Sherry-Ann Brown; Jordan C Ray; Joerg Herrmann
Journal:  J Cardiovasc Transl Res       Date:  2020-04-06       Impact factor: 4.132

Review 9.  Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.

Authors:  Laura C Cappelli; Clifton O Bingham
Journal:  Arthritis Rheumatol       Date:  2021-03-05       Impact factor: 10.995

Review 10.  Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-30       Impact factor: 32.419
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.